CO5271694A1 - Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion - Google Patents

Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion

Info

Publication number
CO5271694A1
CO5271694A1 CO00078367A CO00078367A CO5271694A1 CO 5271694 A1 CO5271694 A1 CO 5271694A1 CO 00078367 A CO00078367 A CO 00078367A CO 00078367 A CO00078367 A CO 00078367A CO 5271694 A1 CO5271694 A1 CO 5271694A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
compounds
inhibitors
metaloproteases
beta
Prior art date
Application number
CO00078367A
Other languages
English (en)
Inventor
Pikul Stanislaw
Eugene Ohler Norman
Kelly Michelle Solinsky
Gregory Almstead Neil
De Biswanath
Michael George Natchus
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5271694A1 publication Critical patent/CO5271694A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La presente invención se relaciona con compuestos que son inhibidores de las metaloproteasas y que son eficaces en el tratamiento de condiciones que se caracterizan por la actividad excesiva de estas enzimas. En particular, los compuestos tienen una estructura según la siguiente fórmula (I): <EMI FILE="00078367_1" ID="1" IMF=JPEG >Donde R1, R2, R3, R4, R5, R6, G y Z tienen los significados que se describen en la especificación. Esta invención también incluye, isómeros, ópticos, diastereómeros y enantiómeros de la Fórmula I, y sales farmacéuticamente aceptables, amidas biohidrolizables, ésteres, e imidas de éstos. Además se describen composiciones farmacéuticas que comprenden estos compuestos, y procedimientos de tratar enfermedades relacionadas a las metaloproteasas utilizando los compuestos o las composiciones farmacéuticas.
CO00078367A 1999-10-14 2000-10-13 Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion CO5271694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15932099P 1999-10-14 1999-10-14

Publications (1)

Publication Number Publication Date
CO5271694A1 true CO5271694A1 (es) 2003-04-30

Family

ID=22572063

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00078367A CO5271694A1 (es) 1999-10-14 2000-10-13 Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion

Country Status (21)

Country Link
EP (1) EP1224171A1 (es)
JP (1) JP2003519100A (es)
KR (1) KR20020038951A (es)
CN (1) CN1379762A (es)
AU (1) AU8014500A (es)
BR (1) BR0014759A (es)
CA (1) CA2386485A1 (es)
CO (1) CO5271694A1 (es)
CZ (1) CZ20021161A3 (es)
HU (1) HUP0203118A3 (es)
IL (1) IL148893A0 (es)
MA (1) MA25561A1 (es)
MX (1) MXPA02003811A (es)
NO (1) NO20021748L (es)
NZ (1) NZ517983A (es)
PE (1) PE20011003A1 (es)
PL (1) PL355764A1 (es)
SK (1) SK5082002A3 (es)
TR (1) TR200200977T2 (es)
WO (1) WO2001027084A1 (es)
ZA (1) ZA200202207B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200305396A (en) * 2002-03-27 2003-11-01 Shionogi & Co Cartilage extracellular matrix degradation
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
EP1689716A1 (en) 2003-12-04 2006-08-16 Wyeth Biaryl sulfonamides and methods for using same
JP2007524567A (ja) 2003-12-04 2007-08-30 ワイス Ｍｍｐ阻害剤としてのビアリールスルホンアミド
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
ATE462698T1 (de) * 2005-06-29 2010-04-15 Janssen Pharmaceutica Nv Verfahren zur synthese von imidazolaminosäurederivaten und verwandten verbindungen
CN107224675B (zh) * 2016-03-25 2023-06-02 南京中硼联康医疗科技有限公司 硼中子捕获治疗***
WO2020206109A1 (en) * 2019-04-02 2020-10-08 The University Of Chicago Remodilins for airway remodeling and organ fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039313A1 (en) * 1998-03-04 1998-09-11 Monsanto Company Thioaryl sulfonamide hydroxamic acid compounds
EP0983267B1 (en) * 1997-03-04 2005-01-26 Pharmacia Corporation Amidoaromatic ring sulfonamide hydroxamic acid compounds
JP2001513484A (ja) * 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
EP1054877A1 (en) * 1998-02-11 2000-11-29 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
BR0009244A (pt) * 1999-03-03 2002-04-16 Procter & Gamble Inibidores de metaloprotease di-hétero substituìdos
HUP0202199A2 (en) * 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors

Also Published As

Publication number Publication date
ZA200202207B (en) 2002-12-24
CN1379762A (zh) 2002-11-13
SK5082002A3 (en) 2002-10-08
CA2386485A1 (en) 2001-04-19
BR0014759A (pt) 2002-07-02
HUP0203118A2 (hu) 2003-01-28
WO2001027084A1 (en) 2001-04-19
IL148893A0 (en) 2002-09-12
PE20011003A1 (es) 2001-09-26
CZ20021161A3 (cs) 2002-08-14
AU8014500A (en) 2001-04-23
MXPA02003811A (es) 2002-09-30
EP1224171A1 (en) 2002-07-24
NO20021748L (no) 2002-06-14
KR20020038951A (ko) 2002-05-24
NZ517983A (en) 2004-01-30
NO20021748D0 (no) 2002-04-12
JP2003519100A (ja) 2003-06-17
MA25561A1 (fr) 2002-10-01
HUP0203118A3 (en) 2003-05-28
PL355764A1 (en) 2004-05-17
TR200200977T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
CO4920241A1 (es) Compuestos inhibidores de metaloproteasas heterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
AR009357A1 (es) Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
AR002718A1 (es) Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos.
CO4920240A1 (es) Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
CO5180642A1 (es) Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
BR0008716A (pt) Inibidores de metaloprotease contendo alquenil ou alquinil
DE69735090D1 (de) Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer&#39;schen krankheit und schmerzen
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion
CO5150190A1 (es) Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f
CO5271694A1 (es) Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion
CO5160251A1 (es) Analogos de prostaglandinas selectivos del receptor fp c16 insaturados
ES2202156T3 (es) Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.
SE0302756D0 (sv) Novel Compounds
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
FI970279A (fi) Orgaanisia yhdisteitä
BR9909268A (pt) C11 oximil e hidroxilamino prostaglandinas úteis como agonistas de fp

Legal Events

Date Code Title Description
FA Application withdrawn